Amphastar Pharmaceuticals (AMPH)
(Delayed Data from NSDQ)
$21.21 USD
+0.26 (1.24%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $21.21 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
A Value C Growth C Momentum A VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
AMPH 21.21 +0.26(1.24%)
Will AMPH be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for AMPH based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for AMPH
Analysts Estimate Amphastar Pharmaceuticals (AMPH) to Report a Decline in Earnings: What to Look Out for
Bausch Health (BHC) Lags Q2 Earnings Estimates
AMPH: What are Zacks experts saying now?
Zacks Private Portfolio Services
What Makes Amphastar (AMPH) a New Buy Stock
Should Value Investors Buy Amphastar Pharmaceuticals (AMPH) Stock?
Here's Why Amphastar (AMPH) is Poised for a Turnaround After Losing 13.1% in 4 Weeks
Other News for AMPH
Amphastar Pharmaceuticals: Shares Are Interesting, And Options Even More
Amphastar Pharmaceuticals Inc (AMPH) Announces Second Quarter 2025 Earnings Release and ...
Amphastar Pharmaceuticals to Release Second Quarter Earnings and Hold Conference Call on August ...
Amphenol (AMPH) Anticipates Strong Q3 Revenue Growth Amid Electronics Boom | AMPH Stock News
Amphastar sees Q3 adjusted EPS 77c-79c, consensus 69c